Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0178874 (
tumor progression
)
40,807
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
RUFY3
is highly expressed in brain tissue and has a role in neuronal development. Transcriptional factor FOXK1 is involved in cell growth and metabolism. We knew that
RUFY3
or FOXK1 has been correlated with the malignant of tumor cells. However, the role of these molecules in colorectal cancer (CRC) progression remains unknown. We investigated the protein expression levels by Western blot, immunofluorescence and immunohistochemistry analyses. The migration and invasive abilities of CRC cells were assessed using shRNA-mediated inhibition in vitro and in vivo. We showed that
RUFY3
expression was up-regulated in CRC compared with its expression in a normal human colon cell line (FHC).
RUFY3
suppression inhibited anchorage independent cell tumorigenesis.
RUFY3
induced elevated expression of eight major oncogenes. Moreover,
RUFY3
physically interacts with FOXK1 in CRC. A positive correlation was observed between the expression patterns of
RUFY3
and FOXK1. Furthermore,
RUFY3
and FOXK1 expression were correlated with
tumor progression
and represented significant predictors of overall survival in CRC patients. SiRNA-mediated repression of FOXK1 in
RUFY3
-overexpressing cells reversed the epithelial-mesenchymal transition (EMT) and metastatic phenotypes. In vivo, FOXK1 promoted
RUFY3
-mediated metastasis via orthotopic implantation. These findings suggest that the
RUFY3
-FOXK1 axis might promote the development and progression of human CRC.
...
PMID:RUFY3 interaction with FOXK1 promotes invasion and metastasis in colorectal cancer. 2862 23